Tumour-targeted chemotherapy with immunoconjugates of calicheamicin (Q35873771)

10 August 2017

1 reference

title

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin (English)

1 reference

10 August 2017

1 reference

Nitin K Damle

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Biological Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

4

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

1445-1452

1 reference

Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Size-selectivity of the glomerular barrier to high molecular weight proteins: upper size limitations of shunt pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

A human Mix-like homeobox gene MIXL shows functional similarity to Xenopus Mix.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Hepatic veno-occlusive disease following hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

The effect of circulating antigen on the biodistribution of the engineered human antibody hCTM01 in a nude mice model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Siglecs, sialic acids and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin (CMA-676) immunoconjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.4.9.1445

10.1517/14712598.4.9.1445

21 January 2018

Identifiers

DOI

1 reference

release_ex23ri4t6zfmdfas7ke7qrzvy4

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ex23ri4t6zfmdfas7ke7qrzvy4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference